Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has been informed by Aciex Therapeutics, Inc. that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent (No. 8,829,005) covering AC-170 Cetirizine Ophthalmic Compositions and a U.S. Patent (No. 8,765,725) covering AC-155 Fluticasone Propionate Nano-crystalline Compositions. With these new patents, AC-170 and AC-155 will have patent protection through March 15, 2030 and January 7, 2033, respectively. For more information, please see the Aciex press release dated October 8, 2014.
Aciex is a private, US-based ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation. On July 1, 2014, Nicox signed an agreement to acquire Aciex, for more information, see the Nicox press release dated July 2, 2014 and the ‘Document E’ registered with the French Autorité des Marchés Financiers (AMF) on September 30, 2014 (E.14-060) (in French, available on Nicox’s website www.nicox.com in the ‘Investor Information’ / ‘Shareholder meetings’ section).